WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406790
CAS#: 867331-64-4 (HCl)
Description: TG-100572 is a potent and selective VEGFR2/Src kinase inhibitor. TG100572 inhibits Src kinases and selected receptor tyrosine kinases, induced apoptosis of proliferating endothelial cells in vitro. TG100572 inhibits downstream molecules involved in the vascular endothelial growth factor (VEGF) signaling pathway resulted in markedly diminished levels of HSV-induced angiogenesis and significantly reduced the severity of SK lesions..
MedKoo Cat#: 406790
Name: TG100572 HCl
CAS#: 867331-64-4 (HCl)
Chemical Formula: C26H27Cl2N5O2
Molecular Weight: 512.435
Elemental Analysis: C, 60.94; H, 5.31; Cl, 13.84; N, 13.67; O, 6.24
Related CAS #: 867331-64-4 (HCl) 867334-05-2 (free base)
Synonym: TG-100572; TG 100572; TG100572; TG-100572 HCl
IUPAC/Chemical Name: 4-chloro-3-(5-methyl-3-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)benzo[e][1,2,4]triazin-7-yl)phenol hydrochloride
InChi Key: NVINBIHNVAYEND-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H26ClN5O2.ClH/c1-17-14-18(22-16-20(33)6-9-23(22)27)15-24-25(17)29-26(31-30-24)28-19-4-7-21(8-5-19)34-13-12-32-10-2-3-11-32;/h4-9,14-16,33H,2-3,10-13H2,1H3,(H,28,29,31);1H
SMILES Code: CC1=C2C(=CC(=C1)C3=C(C=CC(=C3)O)Cl)N=NC(=N2)NC4=CC=C(C=C4)OCCN5CCCC5.Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 512.435 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Sharma S, Mulik S, Kumar N, Suryawanshi A, Rouse BT. An anti-inflammatory role
of VEGFR2/Src kinase inhibitor in herpes simplex virus 1-induced immunopathology.
J Virol. 2011 Jun;85(12):5995-6007. doi: 10.1128/JVI.00034-11. Epub 2011 Apr 6.
PubMed PMID: 21471229; PubMed Central PMCID: PMC3126288.
2: Doukas J, Mahesh S, Umeda N, Kachi S, Akiyama H, Yokoi K, Cao J, Chen Z,
Dellamary L, Tam B, Racanelli-Layton A, Hood J, Martin M, Noronha G, Soll R,
Campochiaro PA. Topical administration of a multi-targeted kinase inhibitor
suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008
Jul;216(1):29-37. doi: 10.1002/jcp.21426. PubMed PMID: 18330892; PubMed Central